Agomab CEO files initial insider holdings
Agomab Therapeutics NV director and Chief Executive Officer Tim Jasper Knotnerus filed an initial ownership report showing his equity position in the company.
Rhea-AI Filing Summary
Agomab Therapeutics NV director and Chief Executive Officer Tim Jasper Knotnerus filed an initial ownership report showing his equity position in the company. The filing lists multiple stock options to buy common shares with exercise prices of $1.1300, $0.0005 and $14.2600, expiring between 2029 and 2036. Some options are fully vested and exercisable, while others vest over time based on continued service. He also reports holding 10,823 common shares directly and 34,394 common shares indirectly through TJK Life Sciences B.V., over which he has voting and dispositive power but disclaims beneficial ownership except for any pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
12 transactions reported
Mixed
12 txns
Insider
Knotnerus Tim Jasper
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Common shares | -- | -- | -- |
| holding | Common shares | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 2,082,875 contracts (Direct);
Common shares — 10,823 shares (Direct);
Common shares — 34,394 shares (Indirect, By TJK Life Sciences B.V.)
Footnotes (6)
- F1. The common shares may be represented by American Depositary Shares, each of which currently represents one common share.
- F2. Shares held by TJK Life Sciences B.V. ("TJK Life Sciences"). The Reporting Person exercises voting and dispositive power over the shares held by TJK Life Sciences and disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
- F3. The shares underlying this option are fully vested and exercisable.
- F4. The exercise prices are reported in U.S. dollars and reflect the conversion from EUR to USD at an exchange rate of $1.1478 per EUR 1.00 as of March 16, 2026.
- F5. 50% of the shares underlying this option vested on February 9, 2026, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
- F6. 25% of the shares underlying this option shall vest on February 9, 2027, with the remainder vesting in thirty-six equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Form 3 filing for Agomab Therapeutics (AGMB) show for CEO Tim Knotnerus?
The Form 3 shows CEO Tim Jasper Knotnerus’ initial ownership in Agomab Therapeutics. It details his direct and indirect common share holdings and several stock option awards with different exercise prices and expiration dates, outlining his current equity-based stake in the company.
What stock options are reported by the Agomab Therapeutics (AGMB) CEO in this Form 3?
The CEO reports multiple stock options to buy common shares with exercise prices of $1.1300, $0.0005 and $14.2600. These options have expiration dates ranging from 2029 through 2036, reflecting a mix of fully vested and time-vesting grants.
Are any of the Agomab Therapeutics (AGMB) CEO’s options fully vested and exercisable?
Yes. A footnote states that the shares underlying at least one option are fully vested and exercisable. Other options follow vesting schedules with portions vesting immediately and the remainder in equal monthly installments, contingent on his continued service with the company.
How are the Agomab Therapeutics (AGMB) CEO’s indirect holdings structured?
Indirect holdings consist of 34,394 common shares held by TJK Life Sciences B.V. The CEO has voting and dispositive power over these shares but expressly disclaims beneficial ownership for Section 16 purposes, except to the extent of any pecuniary interest he might have.
How were the Agomab Therapeutics (AGMB) option exercise prices determined in the Form 3?
The filing notes that exercise prices are reported in U.S. dollars after converting from euros using an exchange rate of $1.1478 per EUR 1.00 as of March 16, 2026, ensuring consistent currency presentation across the reported option grants.
AI-generated analysis. How Rhea-AI works. Not financial advice.
